Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
28 janv. 2021 09h15 HE
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
20 janv. 2021 08h30 HE
|
Interpace Biosciences, Inc.
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million -...
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
14 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
20 août 2020 08h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
24 juin 2020 16h20 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m....
Interpace Biosciences Announces Contract with Lab Benefits Management Firm
27 avr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace...
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
02 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...
Interpace Announces Extension of LabCorp Agreement
24 févr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its...
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
11 févr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement...
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
13 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...